COVID-19. COVID-19
Conditions
Interventions
Intervention 1: Control group: Routine treatment based on physician's opinion and receive placebo syrup (dextrous syrup 60% and edible color, made by Mashhad University of Medical Sciences) 10 cc ever
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 80 Years
Inclusion criteria
Inclusion criteria: Patients who are strongly suspected of having COVID 19 disease in terms of clinical findings and CT scan findings Patients who are clinically classified and hospitalized as severe Patients who have no organ damage. Confirmation of RT-PCR test for SARS-CoV-2 Age under 80 years confirmation of pneumonia by chest x-ray Blood oxygen saturation below 93% Relative stability of the cardiovascular status
Exclusion criteria
Exclusion criteria: Pregnant women Lactating women End stage patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recovery time from the time of randomization of the studied patients to the improvement of clinical symptoms based on 7 common signs of improvement reported by the World Health Organization. Timepoint: before and 14 days after initiation of the intervention. Method of measurement: Relative criteria based on clinical symptoms as follows, 1: not hospitalized with resumption to normal activities, 2: not hospitalized but unable to resume normal activities, 3: hospitalized without the need for oxygen therapy, 4: hospitalized requiring supplemental oxygen, 5: hospitalized and need to receive high-speed oxygen from the nose or non-invasive ventilation or both, 6: hospitalized and need to receive oxygen using invasive ventilation or oxygen delivery from non-pulmonary routes or both, 7: death.;Hospital discharge. Timepoint: After initiation of the intervention. Method of measurement: Duration of hospitalization. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood level of alanine aminotransferase (ALT). Timepoint: Before and 14 days after initiation of the intervention. Method of measurement: spectrometer.;Blood urea nitrogen (BUN) level. Timepoint: Before and 14 days after initiation of the intervention. Method of measurement: spectrometer.;Blood creatinine level. Timepoint: Before and 14 days after initiation of the intervention. Method of measurement: spectrometer.;Blood level of aspartate aminotransferase (AST). Timepoint: Before and 14 days after initiation of the intervention. Method of measurement: spectrometer.;Red blood cell counts. Timepoint: Before and 14 days after initiation of the intervention. Method of measurement: Cell Counter.;White blood cell counts. Timepoint: Before and 14 days after initiation of the intervention. Method of measurement: Cell Counter.;Hemoglobin level. Timepoint: Before and 14 days after initiation of the intervention. Method of measurement: Autoanalyzer.;Hematocrit level. Timepoint: Before and 14 days after initiation of the intervention. Method of measurement: Autoanalyzer.;Erythrocyte sedimentation rate. Timepoint: Before and 14 days after initiation of the intervention. Method of measurement: Wintrobe method.;High-sensitivity C-reactive protein. Timepoint: Before and 14 days after initiation of the intervention. Method of measurement: ELISA kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactVahid Reza Askari
Mashhad University of Medical Sciences
Outcome results
None listed